Ionis Pharmaceuticals
IONS
293 hedge funds and large institutions have $5.68B invested in Ionis Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 93 increasing their positions, 91 reducing their positions, and 22 closing their positions.
114% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 22
27% more capital invested
Capital invested by funds: $4.46B → $5.68B (+$1.22B)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more funds holding
Funds holding: 270 → 293 (+23)
2% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 91
0.47% more ownership
Funds ownership: 89.64% → 90.11% (+0.47%)
8% less call options, than puts
Call options by funds: $56.9M | Put options by funds: $62.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.2M |
| 2 |
Goldman Sachs
New York
|
+$33.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.4M |
| 4 |
BlackRock
New York
|
+$12.3M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17.5M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.1M |
| 4 |
Renaissance Technologies
New York
|
-$10.7M |
| 5 |
SI
Scout Investments
Kansas City,
Missouri
|
-$8.13M |
IONS Hedge Fund Activity: Q2 2017 in Review
293 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2017, worth a combined $5.68B — up 27% from $4.46B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new IONS positions and 22 closed out — a net gain of 25 holders — while 93 added to existing stakes and 91 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $53.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $34.3M.
- 293 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2017, up from 270 in Q1 2017.
- Funds reported $5.68B of Ionis Pharmaceuticals stock for Q2 2017, up 27% quarter-over-quarter.
- 47 funds opened new Ionis Pharmaceuticals positions in Q2 2017 and 22 closed out, a net change of +25 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2017 was Wellington Management Group, an estimated $53.2M added.
- The largest Ionis Pharmaceuticals seller in Q2 2017 was T. Rowe Price Associates, an estimated $34.3M sold.
Based on aggregated 13F filings for Q2 2017.